急性胰腺炎早期胰管支架置入术：一项回顾性研究。

Stenting of the pancreatic duct in the early phase of acute pancreatitis: a retrospective study.

机构信息

Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, 804 Shengli South Street, Xingqing District, Yinchuan, 710004, China.

Department of General Surgery, The Third Affiliated Hospital of Xi'an Medical University, 277 Youyi West Road, Beilin District, Xi'an, 710068, China.

出版信息

BMC Gastroenterol. 2022 Sep 10;22(1):414. doi: 10.1186/s12876-022-02494-5.

DOI:10.1186/s12876-022-02494-5

PMID:36088309

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9463836/

Abstract

BACKGROUND

The effectiveness of pancreatic duct (PD) stenting in the early stages of acute pancreatitis (AP) remains controversial. This study aimed to investigate the efficacy and safety of PD stenting in the early stages of AP.

METHODS

This is a retrospective cohort study. The clinical data of 131 patients with AP from 2018 to 2019 were analysed and divided into two groups: the study group (n = 46, PD stenting) and the control group (n = 85, standard treatment).

RESULTS

There was a statistically significant reduction in pain relief, oral refeeding, hospitalization, and intensive care unit (ICU) stay in the study group compared with that of the control group (P < 0.05). There were no significant differences in the incidence of complications between the two groups. Further multivariate analysis of risk factors for new-onset organ failure showed that the control group (odds ratio [OR] (95% confidence interval [CI]): 6.533 (1.104-70.181)) and a higher level of haematocrit (HCT) at admission (HCT > 46.1%, OR (95%CI): 8.728 (1.264-116.767)) were independent risk factors.

CONCLUSIONS

In the early phase of AP, PD stenting has the potential to reduce pain relief time, oral refeeding time, ICU stay time, and overall hospital stay time. This finding highlights a new route for the treatment of AP.

摘要

背景

在急性胰腺炎（AP）的早期阶段，胰腺管（PD）支架置入的效果仍存在争议。本研究旨在探讨 PD 支架置入在 AP 早期的疗效和安全性。

方法

这是一项回顾性队列研究。分析了 2018 年至 2019 年期间 131 例 AP 患者的临床资料，将其分为两组：研究组（n=46，PD 支架置入）和对照组（n=85，标准治疗）。

结果

与对照组相比，研究组在缓解疼痛、口服喂养、住院和入住重症监护病房（ICU）的时间方面均有统计学意义的降低（P<0.05）。两组并发症的发生率无显著差异。进一步对新发器官衰竭的危险因素进行多因素分析显示，对照组（比值比（95%置信区间）：6.533（1.104-70.181））和入院时较高的血细胞比容（HCT）（HCT>46.1%，比值比（95%置信区间）：8.728（1.264-116.767））是独立的危险因素。